Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

An Antibody Against Trigg… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se
Just nu är det svårt att nå universitetet via telefon på grund av driftstörningar hos Tele2 - Felsökning pågår
Tisdag 25 juni 11:30

An Antibody Against Triggering Receptor Expressed on Myeloid Cells 1 (TREM-1) Dampens Proinflammatory Cytokine Secretion by Lamina Propria Cells from Patients with IBD.

Artikel i vetenskaplig tidskrift
Författare Siggeir Fannar Brynjólfsson
Maria K Magnusson
Philip L Kong
Teis Jensen
Joseph L Kuijper
Katarina Håkansson
Christine B Read
Vibeke W Stennicke
Henrik Sjövall
Mary Jo Wick
Publicerad i Inflammatory bowel diseases
Volym 22
Nummer/häfte 8
Sidor 1803-11
ISSN 1536-4844
Publiceringsår 2016
Publicerad vid Institutionen för biomedicin, avdelningen för mikrobiologi och immunologi
Institutionen för medicin, avdelningen för invärtesmedicin och klinisk nutrition
Sidor 1803-11
Språk en
Länkar dx.doi.org/10.1097/MIB.000000000000...
www.ncbi.nlm.nih.gov/entrez/query.f...
https://gup.ub.gu.se/file/206785
Ämnesord TREM-1, PGLYRP-1, inflammation, ulcerative colitis, Crohn's disease, inflammatory-bowel-disease, dendritic cells, intestinal macrophages, crohns-disease, septic shock, cutting edge, monocytes, homeostasis, responses, immunity, Gastroenterology & Hepatology
Ämneskategorier Gastroenterologi

Sammanfattning

Triggering receptor expressed on myeloid cells 1 (TREM-1) is a potent amplifier of inflammation. Recently, the antimicrobial peptide PGLYRP-1 was shown to be the ligand of TREM-1. Here, the ability of an anti-TREM-1 antibody to dampen the release of proinflammatory cytokines by colon lamina propria cells (LPCs) from patients with IBD was investigated and correlated with PGLYRP-1 levels.Biopsies from patients with ulcerative colitis (UC, n = 45) or Crohn's disease (CD, n = 26) were compared with those from individuals undergoing colonoscopy for other reasons (n = 17). TREM-1 expression was analyzed on myeloid cells by flow cytometry. Cell culture experiments with LPCs were used to analyze PGLYRP-1 and inflammatory cytokine levels and assess the effect of anti-TREM-1 on cytokine secretion.The frequency of TREM-1-expressing neutrophils and recruited macrophages was higher in inflamed than in noninflamed biopsies. The PGLYRP-1 level in inflamed tissue was higher than in noninflamed tissue; it was produced primarily by neutrophils, and its level correlated with the secretion of proinflammatory cytokines. Secretion of myeloperoxidase, tumor necrosis factor-α, interleukin-1β, and interleukin-8 by LPCs stimulated with the potent TREM-1 agonist consisting of PGLYRP-1 complexed with peptidoglycan was reduced in the presence of anti-TREM-1. Moreover, a blocking effect of anti-TREM-1 was apparent when LPCs from a subset of inflamed individuals with elevated PGLYRP-1 were stimulated with killed bacteria.An anti-TREM-1 antibody can dampen secretion of proinflammatory cytokines in inflamed patients with elevated PGLYRP-1. Moreover, PGLYRP-1 + myeloperoxidase is a potential biomarker for predicting the effect of anti-TREM-1 therapy.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?